GLPwatch

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

NCT06221969 · Completed

Last updated 2026-05-28

This study is testing how well the medication CagriSema lowers blood sugar and body weight compared to Tirzepatide in adults with type 2 diabetes who are already taking Metformin, with or without another diabetes medication called an SGLT2 inhibitor.

Status Completed The study has finished.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 1,024 people
Who can join Ages 18+ · all sexes
Timeline Started 2024-01 · est. completion 2026-04
Where 196 sites · Argentina, Australia, Canada, Colombia, India, South Africa, Taiwan, United States

What this study is testing ClinicalTrials.gov NCT06221969 ↗

Description as written by the study sponsor.

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either drug. For each participant, the study will last for up to one and a half years.

Treatments tested

Main thing measuredChange in glycated haemoglobin (HbA1c)
SponsorNovo Nordisk A/S
Conditions studiedType 2 Diabetes
GLP-1 drugs tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06221969 ↗